Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Malaria: A Nested Cohort in a Trial of Radical Curative Regimens

English version České info

In a cohort study within a clinical trial of radical cure regimens for malaria, Cindy S. Chu and colleagues assess the haemolytic risk associated with primaquine treatment among women heterozygous for glucose-6-phosphate dehydrogenase deficiency.

Vyšlo v časopise: Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Malaria: A Nested Cohort in a Trial of Radical Curative Regimens. PLoS Med 14(2): e32767. doi:10.1371/journal.pmed.1002224
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002224

Souhrn

Zdroje

1. Beutler E. The hemolytic effect of primaquine and related compounds: a review. Blood. 1959;14: 103–139. 13618370

2. Beutler E, Mitchell M. Special modifications of the fluorescent screening method for glucose-6-phosphate dehydrogenase deficiency. Blood, J Hematol. 1968;32: 816–818.

3. Luzzatto L. Glucose 6-phosphate dehydrogenase deficiency: from genotype to phenotype. Hematol J. 2006;91: 1303–1306.

4. Bancone G, Chu CS, Somsakchaicharoen R, Chowwiwat N, Parker DM, Charunwatthana P, et al. Characterization of G6PD Genotypes and Phenotypes on the Northwestern Thailand–Myanmar Border. PLoS ONE. 2014;9: e116063. doi: 10.1371/journal.pone.0116063 25536053

5. Nuchprayoon I, Louicharoen C, Charoenvej W. Glucose-6-phosphate dehydrogenase mutations in Mon and Burmese of southern Myanmar. J Hum Genet. 2008;53: 48–54. doi: 10.1007/s10038-007-0217-3 18046504

6. Beutler E, Blume KG, Kaplan JC, Löhr GW, Ramot B, Valentine WN. International Committee for Standardization in Haematology: Recommended Methods for Red-Cell Enzyme Analysis*. Br J Haematol. 1977;35: 331–340. 857853

7. WHO Scientific group. World Health Organization Standardization of procedures for the study of glucose-6-phosphate dehydrogenase. World Health Organ Tech Rep Ser. 1967. pp. 1–53.

8. Bancone G, Chu CS, Chowwiwat N, Somsakchaicharoen R, Wilaisrisak P, Charunwatthana P, et al. Suitability of Capillary Blood for Quantitative Assessment of G6PD Activity and Performances of G6PD Point-of-Care Tests. Am J Trop Med Hyg. 2015;92: 818–824. doi: 10.4269/ajtmh.14-0696 25646252

9. Morris SS, Ruel MT, Cohen RJ, Dewey KG, de la Brière B, Hassan MN. Precision, accuracy, and reliability of hemoglobin assessment with use of capillary blood. Am J Clin Nutr. 1999;69: 1243–1248. 10357746

10. Kheng S, Muth S, Taylor WRJ, Tops N, Kosal K, Sothea K, et al. Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency. BMC Med. 2015;13: 203. doi: 10.1186/s12916-015-0441-1 26303162

11. Hockwald RS, Arnold J, Clayman CB, Alving AS. Toxicitiy of Primaquine in Negroes. J Am Med Assoc. 1952;149: 1568–1570. 14945981

12. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 2008;5: e128. doi: 10.1371/journal.pmed.0050128 18563962

13. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, et al. Vivax Malaria: A Major Cause of Morbidity in Early Infancy. Clin Infect Dis. 2009;48: 1704–1712. doi: 10.1086/599041 19438395

14. World Health Organization. Guidelines for the treatment of malaria, 2nd Edition. Geneva: WHO Press; 2010.

15. Ganesan S, Tekwani BL, Sahu R, Tripathi LM, Walker LA. Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. Toxicol Appl Pharmacol. 2009;241: 14–22. doi: 10.1016/j.taap.2009.07.012 19616568

16. Fasinu PS, Tekwani BL, Nanayakkara NDPD, Avula B, Herath HBMTB, Wang Y-H, et al. Enantioselective metabolism of primaquine by human CYP2D6. Malar J. 2014;13: 507. doi: 10.1186/1475-2875-13-507 25518709

17. World Health Organization. Guidelines for the treatment of malaria, 3rd Edition. Geneva: World Health Organization; 2015.

18. Alving AS, Kellermeyer RW, Tarlov AR, Schrier SL, Carson PE. Biochemical and Genetic Aspects of Primaquine-sensitive Hemolytic Anemia. Ann Intern Med. 1958;49: 240. 13571815

19. Tarlov AR, Brewer GJ, Carson PE, Alving AS. Primaquine sensitivity. Glucose-6-phosphate dehydrogenase deficiency: an inborn error of metabolism of medical and biological significance. Arch Intern Med. 1962;109: 209–234. 13919680

20. Beutler E, Dern RJ, Alving AS. The hemolytic effect of primaquine IV. The relationship of cell age to hemolysis. J Lab Clin Med. 1954;44: 439–442. 13201853

21. Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13: 418. doi: 10.1186/1475-2875-13-418 25363455

22. Recht J, Ashley EA, White NJ. Safety of 8-Aminoquinoline Antimalarial Medicines. Geneva: World Health Organization; 2014.

23. Luzzatto L, Seneca E. G6PD deficiency: A classic example of pharmacogenetics with on-going clinical implications. Br J Haematol. 2014;164: 469–480. doi: 10.1111/bjh.12665 24372186

24. Hanboonkunupakarn B, Ashley EA, Jittamala P, Tarning J, Pukrittayakamee S, Hanpithakpong W, et al. Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects. Antimicrob Agents Chemother. 2014;58: 7340–7346. doi: 10.1128/AAC.03704-14 25267661